{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:36:31Z","timestamp":1790796991945,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2024C03089"],"award-info":[{"award-number":["2024C03089"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373308"],"award-info":[{"award-number":["82373308"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LZ23H160007"],"award-info":[{"award-number":["LZ23H160007"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.canlet.2025.217934","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T21:12:20Z","timestamp":1754428340000},"page":"217934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A novel oncolytic poxvirus carrying CD47 nanomabs in the treatment of pancreatic cancer by reshaping the immune microenvironment"],"prefix":"10.1016","volume":"632","author":[{"given":"Zheling","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6038-7943","authenticated-orcid":false,"given":"Yu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keju","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6075-6895","authenticated-orcid":false,"given":"Hanchu","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7587-312X","authenticated-orcid":false,"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.canlet.2025.217934_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"25","key":"10.1016\/j.canlet.2025.217934_bib2","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"422","key":"10.1016\/j.canlet.2025.217934_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao1641","article-title":"Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy","volume":"10","author":"Bourgeois-Daigneault","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.canlet.2025.217934_bib4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.clon.2022.10.019","article-title":"Chimeric antigen receptor-natural killer cells: a new breakthrough in the treatment of solid tumours","volume":"35","author":"Pan","year":"2023","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217934_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217616","article-title":"Clinical development of immuno-oncology therapeutics","volume":"617","author":"Wang","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217934_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ctrv.2019.06.005","article-title":"Checkpoint inhibitors in pancreatic cancer","volume":"78","author":"Henriksen","year":"2019","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.canlet.2025.217934_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2021.01.031","article-title":"Trials and tribulations of pancreatic cancer immunotherapy","volume":"504","author":"Principe","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217934_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217662","article-title":"Pancreatic cancer precursor lesions - can immunotherapy prevent progression into pancreatic ductal adenocarcinoma?","volume":"619","author":"Enzler","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217934_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217699","article-title":"Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited - exploring the \"Space\"","volume":"622","author":"Brautigam","year":"2025","journal-title":"Cancer Lett."},{"issue":"23","key":"10.1016\/j.canlet.2025.217934_bib10","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-18-0900","article-title":"Immunotherapy in pancreatic adenocarcinoma: beyond \"Copy\/Paste\"","volume":"27","author":"Hester","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"127","key":"10.1016\/j.canlet.2025.217934_bib11","doi-asserted-by":"crossref","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.canlet.2025.217934_bib12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2025.217934_bib13","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1158\/1078-0432.CCR-14-1399","article-title":"Inhibition of CD47 effectively targets pancreatic cancer stem cells via dual mechanisms","volume":"21","author":"Cioffi","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.canlet.2025.217934_bib14","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1158\/1078-0432.CCR-14-2520","article-title":"Molecular pathways: activating T cells after cancer cell phagocytosis from blockade of CD47 \"don't eat me\" signals","volume":"21","author":"McCracken","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.217934_bib15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13045-019-0822-6","article-title":"Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer","volume":"12","author":"Pan","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217934_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-020-00876-4","article-title":"How to select IgG subclasses in developing anti-tumor therapeutic antibodies","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.canlet.2025.217934_bib17","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/cac2.12330","article-title":"Antibody variable region engineering for improving cancer immunotherapy","volume":"42","author":"Lou","year":"2022","journal-title":"Cancer Commun."},{"key":"10.1016\/j.canlet.2025.217934_bib18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2016.12.035","article-title":"Pancreatic cancer: stroma and its current and emerging targeted therapies","volume":"391","author":"Kota","year":"2017","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.canlet.2025.217934_bib19","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/eji.201970107","article-title":"Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)","volume":"49","author":"Cossarizza","year":"2019","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217934_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13059-017-1382-0","article-title":"SCANPY: large-scale single-cell gene expression data analysis","volume":"19","author":"Wolf","year":"2018","journal-title":"Genome Biol."},{"issue":"9","key":"10.1016\/j.canlet.2025.217934_bib21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nmeth.4380","article-title":"Simultaneous epitope and transcriptome measurement in single cells","volume":"14","author":"Stoeckius","year":"2017","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.canlet.2025.217934_bib22","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1038\/s41467-021-26003-6","article-title":"An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma","volume":"12","author":"Xu","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2025.217934_bib23","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1038\/s41467-024-49825-6","article-title":"An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.canlet.2025.217934_bib24","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1158\/2326-6066.CIR-21-1101","article-title":"Molecular subgroups of intrahepatic cholangiocarcinoma discovered by single-cell RNA sequencing-assisted multiomics analysis","volume":"10","author":"Bao","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2025.217934_bib25","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.semcancer.2021.05.019","article-title":"Optimal timing of PD-1 blockade in combination with oncolytic virus therapy","volume":"86","author":"Nguyen","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"11","key":"10.1016\/j.canlet.2025.217934_bib26","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s43018-022-00456-0","article-title":"Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect","volume":"3","author":"Nishiga","year":"2022","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2025.217934_bib27","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41467-020-15129-8","article-title":"Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity","volume":"11","author":"von Roemeling","year":"2020","journal-title":"Nat. Commun."},{"issue":"381","key":"10.1016\/j.canlet.2025.217934_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2968","article-title":"Disrupting the CD47-SIRPalpha anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors","volume":"9","author":"Gholamin","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.canlet.2025.217934_bib29","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41591-019-0498-z","article-title":"Programmable bacteria induce durable tumor regression and systemic antitumor immunity","volume":"25","author":"Chowdhury","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.canlet.2025.217934_bib30","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/s41467-023-37225-1","article-title":"Modular-designed engineered bacteria for precision tumor immunotherapy via spatiotemporal manipulation by magnetic field","volume":"14","author":"Ma","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.217934_bib31","series-title":"Enhancement of Therapeutic Potential of Oncolytic Virus with Homologous Tumor Cell Membranes for Pancreatic Cancer","author":"Chen","year":"2024"},{"issue":"2","key":"10.1016\/j.canlet.2025.217934_bib32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.canlet.2007.02.002","article-title":"Oncolytic viruses in cancer therapy","volume":"254","author":"Vaha-Koskela","year":"2007","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.canlet.2025.217934_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25021180","article-title":"Oncolytic virotherapy: a new paradigm in cancer immunotherapy","volume":"25","author":"Volovat","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.canlet.2025.217934_bib34","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nbt1137","article-title":"Monoclonal antibody therapy of cancer","volume":"23","author":"Adams","year":"2005","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.canlet.2025.217934_bib35","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-Human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2025.217934_bib36","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1166\/jnn.2021.18664","article-title":"Preparation of anti toll-like receptor-4 nano-antibody and its effect on gram negative sepsis","volume":"21","author":"Liao","year":"2021","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.canlet.2025.217934_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216456","article-title":"Oncolytic adenovirus as pancreatic cancer-targeted therapy: where do we go from here?","volume":"579","author":"Yoon","year":"2023","journal-title":"Cancer Lett."},{"issue":"20","key":"10.1016\/j.canlet.2025.217934_bib38","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2018-11-844548","article-title":"Neutrophil plasticity in the tumor microenvironment","volume":"133","author":"Giese","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.canlet.2025.217934_bib39","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20201190","article-title":"Neutrophil-lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC)","volume":"40","author":"Xiang","year":"2020","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.canlet.2025.217934_bib40","article-title":"Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mechanisms","author":"Yao","year":"2024","journal-title":"Cancer Commun."},{"issue":"2","key":"10.1016\/j.canlet.2025.217934_bib41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.canlet.2013.07.014","article-title":"Inflammatory cytokines in human pancreatic cancer","volume":"345","author":"Roshani","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217934_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217466","article-title":"Metabolic reprogramming of neutrophils in the tumor microenvironment: emerging therapeutic targets","volume":"612","author":"Huang","year":"2025","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.canlet.2025.217934_bib43","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-beta: \"N1\" versus \"N2\" TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2025.217934_bib44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","article-title":"The interaction between signal regulatory protein alpha (SIRPalpha) and CD47: structure, function, and therapeutic target","volume":"32","author":"Barclay","year":"2014","journal-title":"Annu. Rev. Immunol."},{"issue":"17","key":"10.1016\/j.canlet.2025.217934_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174261","article-title":"CD47-SIRPalpha checkpoint inhibition enhances neutrophil-mediated killing of dinutuximab-opsonized neuroblastoma cells","volume":"13","author":"Martinez-Sanz","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.canlet.2025.217934_bib46","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s40425-018-0458-z","article-title":"Oncolytic virus immunotherapy: future prospects for oncology","volume":"6","author":"Junaid Raja","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2025.217934_bib47","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/curroncol28010019","article-title":"Andrea gaetano allegra oncolytic Viruses and hematological malignancies: a new Class of immunotherapy drugs","volume":"28","author":"Vanessa Innao","year":"2020","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217934_bib48","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s40425-019-0757-z","article-title":"IL-17 inhibits CXCL9\/10-mediated recruitment of CD8(+) cytotoxic T cells and regulatory T cells to colorectal tumors","volume":"7","author":"Chen","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.canlet.2025.217934_bib49","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.canlet.2025.217934_bib50","first-page":"861","article-title":"Tumor necrosis factor-alpha induces cell type and tissue-specific expression of chemoattractant cytokines in vivo","volume":"142","author":"Ohmori","year":"1993","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217934_bib51","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13045-021-01197-w","article-title":"Targeting CD47 for cancer immunotherapy","volume":"14","author":"Jiang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2025.217934_bib52","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(21)00584-2","article-title":"Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study","volume":"22","author":"Lakhani","year":"2021","journal-title":"Lancet Oncol."},{"issue":"8016","key":"10.1016\/j.canlet.2025.217934_bib53","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-024-07443-8","article-title":"Engineered CD47 protects T cells for enhanced antitumour immunity","volume":"630","author":"Yamada-Hunter","year":"2024","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.canlet.2025.217934_bib54","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","article-title":"Radiotherapy: changing the game in immunotherapy","volume":"2","author":"Demaria","year":"2016","journal-title":"Trends Cancer"},{"issue":"10","key":"10.1016\/j.canlet.2025.217934_bib55","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cac2.12476","article-title":"MFSD2A potentiates gastric cancer response to anti-PD-1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response","volume":"43","author":"Zhang","year":"2023","journal-title":"Cancer Commun."},{"issue":"6","key":"10.1016\/j.canlet.2025.217934_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/v16060870","article-title":"Vaccinia virus: mechanisms supporting immune evasion and successful long-term protective immunity","volume":"16","author":"Hsu","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.canlet.2025.217934_bib57","article-title":"The combination therapy of oncolytic virotherapy","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525005038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525005038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:20:40Z","timestamp":1772788840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525005038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":57,"alternative-id":["S0304383525005038"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217934","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel oncolytic poxvirus carrying CD47 nanomabs in the treatment of pancreatic cancer by reshaping the immune microenvironment","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"217934"}}